{"doi":"10.1002/alz.13382","title":"Plasma NT1‐tau and Aβ<sub>42</sub> correlate with age and cognitive function in two large Down syndrome cohorts","abstract":"Abstract INTRODUCTION People with Down syndrome (DS) often develop Alzheimer's disease (AD). Here, we asked whether ultrasensitive plasma immunoassays for a tau N‐terminal fragment (NT1‐tau) and Aβ isoforms predict cognitive impairment. METHODS Plasma NT1‐tau, Aβ 37 , Aβ 40 , and Aβ 42 levels were measured in a longitudinal discovery cohort ( N = 85 participants, 220 samples) and a cross‐sectional validation cohort ( N = 239). We developed linear models and predicted values in the validation cohort. RESULTS Discovery cohort linear mixed models for NT1‐tau, Aβ 42 , and Aβ 37:42 were significant for age; there was no main effect of time. In cross‐sectional models, NT1‐tau increased and Aβ 42 decreased with age. NT1‐tau predicted cognitive and functional scores. The discovery cohort linear model for NT1‐tau predicted levels in the validation cohort. DISCUSSION NT1‐tau correlates with age and worse cognition in DS. Further validation of NT1‐tau and other plasma biomarkers of AD neuropathology in DS cohorts is important for clinical utility.","journal":"Alzheimer s & Dementia","year":2023,"id":351397,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.925,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":385741,"name":"Kathryn L. Van Pelt","orcid":"0000-0002-5494-2357","position":1,"is_corresponding":false},{"id":7828,"name":"Lei Liu","orcid":"0000-0002-4604-4629","position":2,"is_corresponding":false},{"id":1096451,"name":"Amirah K. Anderson","orcid":null,"position":3,"is_corresponding":false},{"id":316264,"name":"Beth L. Ostaszewski","orcid":null,"position":4,"is_corresponding":false},{"id":80305,"name":"Mark Mapstone","orcid":"0000-0003-0280-8057","position":5,"is_corresponding":false},{"id":270462,"name":"Sid E. O’Bryant","orcid":"0000-0003-0582-5266","position":6,"is_corresponding":false},{"id":632832,"name":"Melissa Petersen","orcid":"0000-0002-3920-5877","position":7,"is_corresponding":false},{"id":270461,"name":"Bradley T. Christian","orcid":"0000-0002-9653-559X","position":8,"is_corresponding":false},{"id":270459,"name":"Benjamin L. Handen","orcid":"0000-0001-9550-1665","position":9,"is_corresponding":false},{"id":7839,"name":"Dennis J. Selkoe","orcid":"0000-0001-8846-9767","position":10,"is_corresponding":false},{"id":245004,"name":"Frederick A. Schmitt","orcid":"0000-0003-4315-2488","position":11,"is_corresponding":false},{"id":270466,"name":"Elizabeth Head","orcid":"0000-0003-1115-6396","position":12,"is_corresponding":false},{"id":656449,"name":"Andrew M. Stern","orcid":"0000-0002-8589-6891","position":0,"is_corresponding":true}],"reference_count":33,"raw_metadata":null,"created_at":"2026-07-19T01:12:41.740237Z","pmid":"37438872","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}